You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
20 May 2026 - Medical technology company Implantica AG (Nasdaq First North Premier Growth Market: IMP A SDB) announced on Wednesday that it has submitted its final response to the US Food and Drug Administration (FDA) regarding Module 3 of the Premar...
20 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to provide GMP-grade opDNA starting material for a Phase ...
20 May 2026 - Biotechnology company MEKanistic Therapeutics announced on Tuesday that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug application for MTX-531, its lead oncology candidate.Subject to standard start-up...
20 May 2026 - Biotechnology company Matter Bio announced on Tuesday the submission of its first Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for Lm-LLO-TT for a first-in-human Phase 1/2a clinical trial in pa...
20 May 2026 - Myosin Therapeutics, a clinical stage biotechnology company developing therapies for oncology, announced on Tuesday that the first patient has been dosed in the Phase 1/2 STAR-GBM study of its lead programme, MT-125.MT-125 is a first-in...
19 May 2026 - Clinical-stage biotechnology company Nanjing Leads Biolabs Co Ltd (HK:9887) announced on Monday that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE...
19 May 2026 - Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors ...